|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
ISO |
Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 |
|
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
App |
amyloid beta precursor protein |
increases secretion |
ISO |
Creatine analog results in increased secretion of APP protein modified form |
CTD |
PMID:22906069 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
ISO |
Sirolimus inhibits the reaction [Creatine results in increased expression of BDNF protein] |
CTD |
PMID:33022268 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
[Creatine co-treated with Ribose] results in decreased activity of CASP3 protein |
CTD |
PMID:21220914 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine] |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions |
ISO |
[CSF3 protein co-treated with Paclitaxel] results in decreased abundance of Creatine |
CTD |
PMID:9018096 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Dek |
DEK proto-oncogene |
increases chemical synthesis |
ISO |
DEK protein results in increased chemical synthesis of Creatine |
CTD |
PMID:28558019 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Gatm |
glycine amidinotransferase |
increases chemical synthesis |
ISO |
GATM protein results in increased chemical synthesis of Creatine |
CTD |
PMID:16820567 |
|
NCBI chr 3:109,658,919...109,675,508
Ensembl chr 3:109,658,951...109,684,129
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation multiple interactions |
ISO |
Creatine results in increased phosphorylation of MTOR protein Sirolimus inhibits the reaction [Creatine results in increased phosphorylation of MTOR protein] |
CTD |
PMID:33022268 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Creatine results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
[coenzyme Q10 co-treated with Creatine] results in decreased expression of SNCA protein |
CTD |
PMID:19476553 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
increases abundance |
ISO |
ARNTL gene mutant form results in increased abundance of Creatinine |
CTD |
PMID:27056296 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine] |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Creatinine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Lepr |
leptin receptor |
affects abundance multiple interactions increases abundance |
ISO |
LEPR affects the abundance of Creatinine Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Creatinine] |
CTD |
PMID:20567778 PMID:29988851 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[NFE2L2 protein affects the susceptibility to ochratoxin A] which results in increased abundance of Creatinine |
CTD |
PMID:28710020 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[SC 560 results in decreased activity of PTGS1 protein] which results in increased abundance of Creatinine |
CTD |
PMID:19629487 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Creatinine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Creatinine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases abundance |
ISO |
SOD2 protein results in decreased abundance of Creatinine |
CTD |
PMID:19917352 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Phosphocreatine inhibits the reaction [Doxorubicin results in increased expression of BAX protein]; Phosphocreatine inhibits the reaction [Pyruvaldehyde results in increased expression of BAX protein]; Phosphocreatine inhibits the reaction [Streptozocin results in increased expression of BAX protein] |
CTD |
PMID:34358621 PMID:34455488 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Phosphocreatine inhibits the reaction [Pyruvaldehyde results in decreased expression of BCL2 protein]; Phosphocreatine inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein] |
CTD |
PMID:34455488 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
7-oxozeanol inhibits the reaction [Phosphocreatine inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]; Phosphocreatine inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Phosphocreatine inhibits the reaction [Pyruvaldehyde results in decreased expression of CASP3 protein]; Phosphocreatine inhibits the reaction [Pyruvaldehyde results in increased expression of CASP3 protein modified form]; Phosphocreatine inhibits the reaction [Streptozocin results in decreased expression of CASP3 protein]; Phosphocreatine inhibits the reaction [Streptozocin results in increased expression of CASP3 protein modified form] |
CTD |
PMID:34358621 PMID:34455488 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Phosphocreatine inhibits the reaction [Pyruvaldehyde results in decreased expression of CASP9 protein]; Phosphocreatine inhibits the reaction [Streptozocin results in decreased expression of CASP9 protein] |
CTD |
PMID:34455488 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
Phosphocreatine inhibits the reaction [Pyruvaldehyde results in increased expression of CYCS protein]; Phosphocreatine inhibits the reaction [Streptozocin results in increased expression of CYCS protein] |
CTD |
PMID:34455488 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
EXP |
Phosphocreatine inhibits the reaction [Doxorubicin results in decreased expression of FOXO3 protein] |
CTD |
PMID:34358621 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
Phosphocreatine inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of GSK3B protein]; Phosphocreatine inhibits the reaction [Pyruvaldehyde results in decreased phosphorylation of GSK3B protein]; Phosphocreatine inhibits the reaction [Streptozocin results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:34455488 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP |
Phosphocreatine inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of IRS1 protein]; Phosphocreatine inhibits the reaction [Pyruvaldehyde results in decreased phosphorylation of IRS1 protein]; Phosphocreatine inhibits the reaction [Streptozocin results in decreased phosphorylation of IRS1 protein] |
CTD |
PMID:34455488 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
multiple interactions |
EXP |
7-oxozeanol inhibits the reaction [Phosphocreatine inhibits the reaction [Doxorubicin results in decreased expression of MAP3K7 protein]]; Phosphocreatine inhibits the reaction [Doxorubicin results in decreased expression of MAP3K7 protein]; Phosphocreatine inhibits the reaction [Doxorubicin results in increased expression of MAP3K7 protein] |
CTD |
PMID:34358621 |
|
NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Phosphocreatine inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein] |
CTD |
PMID:34358621 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ppid |
peptidylprolyl isomerase D |
multiple interactions |
EXP |
Phosphocreatine inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of PPID protein]; Phosphocreatine inhibits the reaction [Pyruvaldehyde results in increased expression of PPID protein]; Phosphocreatine inhibits the reaction [Streptozocin results in increased expression of PPID protein] |
CTD |
PMID:34455488 |
|
NCBI chr 2:164,727,803...164,740,168
Ensembl chr 2:164,727,779...164,740,221
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
multiple interactions |
EXP |
Phosphocreatine inhibits the reaction [Doxorubicin results in increased expression of RIPK3 protein] |
CTD |
PMID:34358621 |
|
NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121
|
|
G |
Sod3 |
superoxide dismutase 3 |
multiple interactions |
EXP |
Phosphocreatine inhibits the reaction [Doxorubicin results in decreased expression of SOD3 protein] |
CTD |
PMID:34358621 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases response to substance multiple interactions |
EXP |
STAT3 protein results in increased susceptibility to Phosphocreatine Phosphocreatine inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased phosphorylation of STAT3 protein]; Phosphocreatine inhibits the reaction [Pyruvaldehyde results in increased phosphorylation of STAT3 protein]; Phosphocreatine inhibits the reaction [Streptozocin results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:34455488 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|